Friday, 18 May 2018

Lung Cancer Market Segmentation Detailed Study with Forecast Up To 2018

Market Synopsis of Global Lung Cancer Market:
Market Scenario:
Lung cancer is a malignant lung tumor characterized by uncontrolled cell growth in lung tissue with symptoms such as coughing, weight loss, fatigue and chest pain. The two types of lung cancers are small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). The NSCLC type accounts for almost 80% of the cancers with NSCLC representing the remaining. The cure rates for the two types of lung cancers are different and the SCLC being the most malignant. The cure rates also depend on the stage of cancer detection with rates varying by 55% for first stage to just 1% for stage IV.
The global market of Lung Cancer is expected to reach USD 36929.8 million in 2023 from USD 15219.7 million in 2016 with a CAGR of 13.5% during the forecast period 2017-2023.

Global Lung Cancer Market, by Types, 2016 (%):

Intended Audience
  • Lung Cancer Drug Manufacturers
  • Cancer research facilities
  • Market Research and Consulting Service Providers
  • Hospitals & Research Laboratories

Key Players for Global Lung Cancer Market: 
Some of the key players in this market are: F. Hoffmann-La Roche AG, Novartis, PFIZER INC, Merck & Co., Inc., BRISTOL-MYERS SQUIBB, ELI Lilly and Company, Sanofi and others.

Segments:
Global Lung Cancer Market has been segmented on the basis of types which comprises of SCLC and NSCLC. On the basis of treatments it is segmented into Surgery, Chemotherapy, Radiotherapy, Photodynamic therapy (PDT) and Laser therapy. On the basis of end users, it includes Hospitals & Clinics, Cancer Research Centers and Laboratories.

Regional Analysis of Global Lung Cancer Market:
The global market for Lung Cancer is growing steadily. The global lung cancer market on the basis of region comprises of North America, Europe, Asia Pacific and Middle East & Africa. The global market for Lung Cancer is growing with the CAGR of 13.5% during the forecast period from 2017-2023. NSCLC is the most common type of lung cancer globally. The global Lung Cancer market reached USD 36929.8 million in 2023 from 15219.7 million in 2016. Europe region captured the second largest market globally and is expected to reach USD 8,536.3 million by 2023 due to the growing demand and need for lung cancer drugs, and the growing prevalence of lung cancer.
The report for Global Lung Cancer Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Posted by at No comments:

Mental Health Software and Devices Market Top Trends, Regulations and Competitive Landscape Outlook To 2023

Market Scenario:
Mental Health Software and Devices is an abrasive process used to gently sand the thicker and uneven layers of skin. According to the American Society for Aesthetic Plastic Surgery, Mental Health Software and Devices is used for the treatment of hyperpigmentation, acne & trauma scars, photo-damage, and stretch marks. There is an increasing demand for minimally invasive cosmetic procedures which is an important driver for the growth of the market. According to the American Society of Plastic Surgeons, about 15.9 million surgical and minimally-invasive cosmetic procedures were performed in the U.S. in 2015. Additionally, development of new technologically advantaged devices, and increasing demand for cosmetics also influence the growth of the market. Increasing number of non-surgical procedures, offering enormous benefits such as quick recovery, reduced time of treatment, and better results than other cosmetic surgical procedures is also influencing the growth of this market. Furthermore, attraction of the youth towards western lifestyle and extensive use of cosmetics for skin care accelerate the growth of the market. However, the growth of the market is restrained by the availability of alternative treatments such as chemical peel and laser skin resurfacing. The acceptance of the laser resurfacing is increasing. According to the American Society of Plastic Surgeons, the number of laser skin resurfacing procedures in 2016 reached approximately to 586,662 from 569,458 in 2015.

The market for global Mental Health Software and Devices is expected to reach USD 802.44 million by 2023 from USD 609.79 million in 2016, at a CAGR of 3.42% from 2017 to 2023.
Intended Audience
  • Pharmaceutical companies
  • Biotechnological institutes
  • Research and Development (R&D) Companies
  • Medical Research Laboratories
  • Market Research and Consulting Service Providers
Segmentation
The global Mental Health Software and Devices market is segmented on the basis type, product, indication, and end user.
On the basis of type, the market is segmented diamond Mental Health Software and Devices, crystal Mental Health Software and Devices, and others. On the basis of product, the market is categorised into Mental Health Software and Devices machine, Mental Health Software and Devices crystals, Mental Health Software and Devices tips, Mental Health Software and Devices creams and scrubs, and others. The Mental Health Software and Devices machine segment is sub-segmented into table top, hand-held, and others. The Mental Health Software and Devices crystals segment is sub-segmented into aluminium oxide crystals, sodium bicarbonate crystals, sodium chloride crystals, and others. The Mental Health Software and Devices tips segment is sub-segmented into diamond tips, bristle tips, and others.
On the basis of indication, the market is segmented into acne & trauma scars, hyperpigmentation, photo-damage, stretch marks, and others. On the basis of end users, the market is segmented into hospitals, dermatology clinics, home care, and others.
Regional Analysis
The Americas dominates the global Mental Health Software and Devices market owing to increasing adoption of new technologies for addressing various dermal conditions like acne, stretch marks, hyperpigmentation, and others. Additionally, rising demands for minimally invasive procedures within the region is boosting the market growth.
Europe is the second largest market, in the global Mental Health Software and Devices market owing to increasing adoption of the technology for the treatment of skin related problems within the region. Moreover, huge patient population and rising healthcare expenditure facilitates the market growth within the region. According to the British Skin Foundation in 2016, about 60% of the British population was estimated to have suffered from some kind of the skin disease. Moreover, approximately 28% of the population within the region admitted to witness acne at some stage during their lifetime.
Asia pacific region is the fastest growing market. Increasing prevalence of acne and rising demands for minimally invasive procedures is facilitating the market growth within the region. According to the Cosmetic Physicians College of Australasia in 2015, the Australians spent approximately USD 890 million on minimally or non-invasive cosmetic procedures. The estimated rise was of 5% from 2014.
The Middle East & Africa has the least share in the global Mental Health Software and Devices market due to presence of poor economies especially in the African region. Majority of the market of Middle & Africa region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure by the presence of the economies like Saudi Arabia, Kuwait and Qatar within the region.

 Key players for global Mental Health Software and Devices market
The key players for the global Mental Health Software and Devices market are Johnson & Johnson Services Inc., Procter & Gamble, Koninklijke Philips N.V., Altair Instruments, Silhouet-Tone, Advanced Microderm, Inc., Dermaglow, New Shining Image LLC., Lasertec Medical Service, Delasco, and others.

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at 1 comment:

Thursday, 17 May 2018

Tumor Necrosis Factor Alpha Inhibitors Market Top Trends, Regulations and Competitive Landscape Outlook To 2023

Market Scenario:
The tumor necrosis factor alpha (TNF-a) inhibitors represent one of the major treatment methods for inflammatory diseases. Globally, this drug class is known to be the most successful drugs in the overall pharmaceutical industry. Several conditions such as inflammations, rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and seronegative spondyloarthropathies, can be treated with the help of these drugs. The total sales of the top three blockbuster TNF-alpha inhibitors namely Remicade, Enbrel, and Humira had surpassed USD 32 billion in 2016.
Xalud’s lead product XT-150 harnesses the power of the body’s potent anti-inflammatory protein IL-10 to treat inflammatory diseases of the central nervous system (CNS) and joints. XT-150 is in the stage of the preclinical trials for multiple sclerosis, neuropathic pain, and osteoarthritis. In leading rodent model study for neuropathic pain XT-150 has been highly efficacious. Single injection delivers it into the fluid surrounding the spinal cord ensuring that the therapy reaches its target.
In the present scenario, developing countries have stringent regulatory requirements for approval of a new drug. It is a difficult task for marketing authorization application to get single regulatory for a new drug product which belongs to various categories of drugs such as NCE, biologicals, controlled drugs, etc. Therefore, the knowledge of precise and detailed regulatory requirements for market authorization application of different categories of drugs should be known to establish a suitable regulatory strategy. There is a need for pronounce and a fine balance between the persistence of gaining market access to pharmaceuticals, to protect the public health and facilitate healthy growth of pharmaceutical manufacturers.
The global tumor necrosis factor alpha inhibitors market is expected to grow at a CAGR of approximately 7.1% during the forecast period 2017-2023.
Intended Audience
  • Tumor Necrosis Factor Alpha Inhibitors Drug Suppliers
  • Tumor Necrosis Factor Alpha Inhibitors Drug Manufacturers
  • Research and Development (R&D) Companies
  • Medical Research Laboratories
  • Academic Medical Institutes and Universities
  • Research Methodology

Segmentation                                                                                                
The global tumor necrosis factor alpha inhibitors market is segmented on the basis of the drug, disorder type, route of administration, stage of clinical trials, and application.
On the basis of the drug, the global tumor necrosis factor alpha inhibitors market is segmented into Humira, Enbrel, Remicade, and others
On the basis of the disease type, the global tumor necrosis factor alpha inhibitors market is segmented into Alzheimer's diseases, Parkinson's diseases, ischemic stroke, multiple sclerosis, and others.
By the route of administration, the global tumor necrosis factor alpha inhibitors market is segmented into oral, subcutaneous, intravenous, and others.
On the basis of the stage of clinical trials, the global tumor necrosis factor alpha inhibitors market is segmented into the preclinical trial, phase 1 clinical trial, phase 2 clinical trial, phase 3 clinical trial, and phase 4 clinical trial.
On the basis of the application, the global tumor necrosis factor alpha inhibitors market is segmented into medicine, scientific research, and others.
Regional Analysis
The global tumor necrosis factor alpha inhibitors market is segmented as the Americas, Europe, Asia Pacific and the Middle East and Africa.
The Americas is projected to hold the largest share of the global tumor necrosis factor alpha inhibitors market. P2D Biosciences, a US-based company, received $ 2.3 million funding from NIH (National Institutes of Health) with four grants. The grants include the development of new drugs for the treatment of acute leukemia and Alzheimer's disease and a new drug to improve stem cell transplant therapy for treating leukemia and lymphomas, which will help P2D to develop medical advances that improve the lives and health of people who are affected with these diseases.
Europe is expected to capture the second lead in this market in the coming five years owing to substantial technological advancements. In 2016, LEO Pharma, a Denmark based company entered biologics through a strategic partnership with AstraZeneca. The partnership will help LEO Pharma enhance their product portfolio. A strategic alliance with a healthcare giant will help LEO pharma expand their geographic presence and become a world leader in dermatology segment.
Moreover, Asia Pacific is expected to witness the fastest growth rate over the forecast period. The Middle East and Africa are also expected to show healthy growth in the coming five years.
Key Players
In May 2016, Pfizer acquires Anacor for its inflammatory & immunology portfolio. Anacor is a biopharmaceutical company focused on small molecule therapeutics from its boron chemistry platform, and its asset Crisaborole is in FDA review if approved will be a first-line treatment option for patients with atopic dermatitis. They have entered into a definitive merger agreement under which Pfizer will acquire Anacor for approximately $5.2 billion which assumes the conversion of Anacor’s outstanding convertible notes. Anacor will be a strong fit with Pfizer’s innovative business due to the strategic focus on inflammation and immunology and is expected to enhance near-term revenue growth for the innovative business.
Some of key the players in the global tumor necrosis factor alpha inhibitors market are AbbVie Inc. (U.S.),  Ablynx (Belgium), Apogenix GmBH (Germany), AryoGen Biopharma (U.S.), Bionovis (Brazil), CASI Pharmaceuticals (U.S.), Celltrion Healthcare (South Korea.), Celgene Corporation (U.S.), Delenex Therapeutics (Switzerland), Dexa Medica (Indonesia), EPIRUS Biopharmaceuticals (U.S.), Janssen Biotech (U.S.), GlaxoSmithKline Inc. (U.S.), HanAll Biopharma (South Korea.), Intas Pharmaceuticals (India), LEO Pharma (Denmark), LG Life Sciences (U.S.), MedImmune (U.S.), Momenta Pharmaceuticals (U.S.), Novartis AG (Switzerland), Sanofi-Aventis (France), Zydus Cadila (India), and others.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Current and forthcoming E-Prescribing Systems Market size in terms of volume and value 2018

Market Scenario:
E-prescribing or electronic prescribing is a technology that helps in the generation and electronic transmission of prescriptions from a physician to pharmacists. E-prescribing helps in improving the safety and quality of patient care and enable access to patient history to ensure better care.
The global e-prescribing systems market is estimated to register a healthy growth. The market is majorly driven by the increasing government initiatives and incentive programs to improve quality of healthcare, to cut healthcare cost, and reduce prescription errors. Additionally mandate healthcare programs and projects in the developed countries are propelling the growth of the global e-prescribing systems market.
The Global E-Prescribing systems market is expected to grow at a CAGR of 21% during the forecast period.
Intended Audience
  • Pharmaceutical Manufacturers and Suppliers
  • Medical Research Laboratories
  • Research and Development (R&D) Companies
  • Market Research and Consulting Service Providers
  • Potential Investors
Segments                                                                                                                                            
The global e-prescribing systems market is segmented on the basis of system type, mode of delivery, component, and end users.
On the basis of the system type, the market is segmented as Stand-alone system, and Integrated system.
On the basis of mode of delivery, the market is segmented into Cloud-based, Web-based, and on-premise.
On the basis of by component, the market is segmented into Software, Hardware, and Services.
On the basis of end user, the market is segmented into Hospitals, Clinics and Pharmacy.
Regional Analysis
North America holds the maximum share of e-prescribing systems market in the Americas region. On a regional basis, the Americas is segmented into North America and South America. North America is segmented into the U.S. and Canada. Rising government initiatives and funding has increased the scope of the E-prescribing systems market in North America.
Europe accounts for a healthy market share due to factors such as rising healthcare networks and healthcare related projects. Growing healthcare expenditure and infrastructure is driving the e-prescribing systems market in Europe. For instance, adoption of the European Patient Smart Open Services in 2013, has led to the electronic submission of patient summaries and prescription.
Asia Pacific is the expected to register the fastest growth rate for the e-prescribing systems market. The high growth rate is attributed to rising healthcare organizations, growing healthcare programmes, and projects to enhance patient care and safety. Additionally, active inclination towards digitization to reduce human errors and frauds, increasing healthcare expenditure, and demand for new technology is fuelling the market growth.
The Middle East & Africa is expected to show slow growth in the market . Major factors that are likely to hamper the growth are lack of awareness regarding patient management software, and  limited access and availability of treatment facilities. In the Middle East, United Arab Emirates  has garnered the largest market share owing to the development of healthcare infrastruture and rising number of specialty care centers.
Key Players                                                                                                         
Some of the key players in the e-prescribing systems market are Aprima, Cerner Corporation, eClinicalWorks, Practice Fusion, Inc., eMDs, Inc., Surescripts , Allscripts, iMedX Inc., Athena health Inc., and Henry Schein e-prescribe.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Hip Tendinitis Market Dynamics, Forecast, Analysis and Supply Demand 2018

Market Scenario:
Hip tendonitis refer to a condition in which single or many tendons connects various muscles to the hip bone, get damaged. The hip and pelvis joints supports the body weight in an upright position. The muscles present in this region are more bulky and strong, however, tendons are prone to damage with increasing age and changing lifestyle. During the last decade, the lifestyle of the people across the globe has changed dramatically. Increasing incident of sports injuries, rising geriatric population, increasing patients population suffering from rheumatoid arthritis & diabetes, and adoption of sedentary lifestyle have led to increase the prevalence of hip tendonitis, which significantly drives the market growth. According to the US centers for diseases control, over 10% of kids and teen participating in the sports suffer from minor or major types of injuries. Additionally, increasing government support for research & development of different drugs, changing lifestyle and lack of exercise have fuelled the market growth. However, long approval time for drugs and lack of precise treatment may slow the growth of the market.
The global hip tendinitis market is expected to grow at a CAGR of 4.55% during forecast period 2017-2023. 
Intended Audience
  • Pharmaceutical companies
  • Biotechnological institutes
  • Government and Private Laboratories
  • Research and Development (R&D) Companies
  • Medical Research Laboratories
  • Market Research and Consulting Service Providers 
Segmentation
The global hip tendinitis market is segmented on the basis of types, treatment, and end users.
On the basis of types, the market is segmented into internal snapping hip, external snapping hip, and intra-articular snapping hip.
On the basis of treatment, the market is segmented into diagnosis and therapy. The diagnosis is further segmented into physical exam, imaging tests, and others. Imaging test is further segmented into ultrasound, magnetic resonance imaging (MRI) scans, and others. The therapy is segmented into pharmacological, non-pharmacological, shock wave or surgery, medical devices, and others. The pharmacological therapy is further segmented into OTC drugs, corticosteroids injections, platelet-rich plasma (PRP), and others. The medical devices are further segmented into mechanical band, support tape, pre-cut strips, continuous rolls, and others.
On the basis of end users, the market is segmented into hospitals & clinics, medical research centers, academic institutes, and others. 
Regional Analysis
The global hip tendinitis market is dominated by America owing to the presence of huge geriatric population and continuous increasing number of diabetic patients. As per the report published by the population reference bureau, in 2015, the number of Americans ageing over 65 were 46 million, which is expected to reach over 98 million by 2060. Furthermore, increasing number of patients suffering form rheumatoid arthritis, changing lifestyle, and huge healthcare spending have boosted the growth of the market in America. According to the American Diabetes Association, over 30.3 million Americans population were suffering from diabetes in 2015. Additionally, increasing awareness among the people regarding different types of diseases and increasing government support is likely to contribute to the growth of the market during the review period 2017-2023.
Europe accounts for the second largest hip tendinitis market, which is followed by Asia Pacific. According to the Eurostat, in 2016, 19.2% of total European population were over age 65 years. Increasing geriatric population and adoption of sports by the people may drive the market growth. Moreover, availability of funds for research, and government support for research & development are expected to fuel the market growth.
Asia Pacific is the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, and the presence of huge opportunity in the market. On the other hand, the Middle East & Africa holds the least share in the global hip tendinitis market due to presence of poor economy, especially, in African region. The Middle East holds the major share of the Middle East & African market owing to the well-developed healthcare sector and huge healthcare expenditure. 
Key players for global hip tendinitis market
Some of the key players in the global hip tendinitis market are Almatica Pharma, Inc (U.S.), AstraZeneca (U.K.), Bayer AG (Germany), Boehringer Ingelheim Pharmaceuticals, Inc (Germany), Merck & Co., Inc (U.S.), Pfizer (U.S.), Abbott (U.S.), GlaxoSmithKline plc (U.K.), Teva Pharmaceuticals (Taiwan), Lupin Pharmaceuticals, Inc. (India), Geri-Care Pharmaceuticals. (U.S.), and Perrigo Company (U.S),
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Embolization Particle Market Top Trends, Regulations and Competitive Landscape Outlook To 2023

Market Scenario
Embolization is a minimally invasive therapy to stop bleeding as well as to stop blood flow to a tumor in order to shrink it or in preparation for removal. In this procedure, some embolized particles or substances are injected into the veins of the patients to block or reduce the blood flow to cancer cells. Embolization is an option for some patients with tumors that cannot be removed by surgery. It can be used for tumors that are too large to be treated with ablation (usually larger than 5 cm thickness). It can also be used with ablation. Embolization does reduce some of the blood supply to the normal liver tissue, so it may not be a good option for some patients whose liver has been damaged by diseases such as hepatitis or cirrhosis. Embolization is used in many procedures as a part of interventional radiology.
The embolization particle market is expecting a healthy growth during the forecast period. With the growing use of embolization technique as a treatment for conditions other than cancer such as vascular malformations and fibrosis is fuelling the demand for embolization particles globally. Continuous introduction of technically advanced products with enhanced efficiency is also supporting the global market growth.
According to World Health Organization, an estimated 17.7 million people died from cardiovascular diseases in 2015, representing 31% of all global deaths
Total number of global volume of cardiovascular procedures is expected to increase on average by 3.7% per year to over 18.73 million corresponding to surgeries and transcatheter interventions in the year 2022
However, less number of interventional neuroradiologists and interventional neuroradiology (INR) labs and strict regulatory rules may hamper the market growth during the forecast period.
The global embolization particle market is expected to grow at a CAGR of 9.64% during the forecast period 2017-2023.
Segmentation                                                                                                                                      
The global embolization particle market is segmented on the basis of product type, application, level of occlusion and end user.
On the basis of the product type the embolization particle market is further segmented into radioembolization and drug eluting beads.
On the basis of applications, the market is segmented into oncology, urology, peripheral vascular disease, neurology, and others.
On the basis of level of occlusion the market is segmented into proximal and distal.
On the basis of end user, it is segmented into hospitals & clinics, ambulatory services and others.


Key Findings
  • The market for embolization particle is expected to reach around USD 1,909.76 million by 2023.
  • Radioembolization accounts the largest market share in 2016 and which is projected grow at a CAGR of 10.01% during the forecast period from 2017-2023.
  • Americas hold the largest share of the embolization particle market and is expected to reach USD 703.13 million by 2023.
  • Asia Pacific is the fastest growing region across the globe and expected to grow at a rate of CAGR 10.11% during the forecast period. 
Regional Analysis
The Americas dominate the global embolization particle market owing to the presence of strong economic condition, huge development in the healthcare domain, and focus of research institutions on updating technology for new and advanced diagnosis and treatment methods. Moreover, advanced hospitals infrastructures, and availability of skilled healthcare professional is further adding fuel to the growth of the market.  
Europe holds the second position in the market on the basis of increasing emphasis on rapid diagnosis and treatment of cancer, changing lifestyle, increasing prevalence of cancer among geriatric population. As per the Organization for Economic Co-operation and Development (OECD), Germany spent 11% of the total GDP on healthcare in 2013, which was 10.8% in 2012, which drives the growth of the market in this region. 
Asia Pacific is the fastest growing market owing to more number of developing nations present in this region, for instance, countries like India and China. These countries are encouraging the growth of the healthcare domain. Furthermore, increasing patient population from cancer in developing countries will directly increase the demand for various diagnosis & treatment methods, which, in turn, will boost the growth of the market.    
The Middle East & Africa is expected to hold the least market share due to less availability of medical facilities, and less development in the healthcare domain. However, countries such as Qatar and Kuwait are focusing more on the healthcare domain and developing medical facilities, which will boost the market of this region. 
Key Players                                                                                                         
Some of the key players in this market are Boston Scientific Corporation, Guerbet, BTG International Ltd, Medtronics, Sirtex, Terumo, and Merit Medical.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels: , ,

Wednesday, 16 May 2018

Asia Pacific Sterility Testing Market Expected to Grow at High Cagr during Forecast Period 2018 – 2022

Market Scenario
Sterility testing plays an important role in the healthcare sector. It ensures the purity and safety of the product or a substance. This is a vital regulatory requirement for both pharmaceutical and medical device companies when bringing a product to market or assessing the post-launch safety of a product or device. It is an essential part of every sterilization validation and is an extremely difficult process that must be designed and executed for eliminating false positive results, which, are generally due to laboratory contamination from the testing environment or technician error.

The major driving factor for the growth of the market are increasing manufactures of the medical devices & products, increasing prevalence of many infectious diseases, and increasing in the Research and development projects in life sciences. Increasing number of diseases has intensified the research activity which has significantly driven the market. Currently, about 27 million deaths occur each year in South and East Asia, 7 million among those are under 30 years of age, and 10 million fall in the middle-aged group. Beside this, huge population base in this region, rising outsourcing in the pharmaceutical sector to the emerging nations such as India and China, and rapid development in economy has provided a support for the growth of the market. Furthermore, growth of pharmaceutical industries, technological advances, increasing support provided by government and, the increasing R&D investments have fuelled the market growth in this region. However, a cumbersome approval process and strict regulatory rules are few factors responsible for restraining the market growth.
Sterility also relies on procedural measures that effectively prevent contamination of biological materials, such as clean room technology and other Good Manufacturing Practices.
The Asia Pacific sterility testing market is expected to grow at a CAGR of 10.2% during 2017-2023 
Intended Audience
  • Product manufacturers of sterility product
  • Sterility Testing Product Distributors
  • Government and private research companies
  • Research and Development (R&D) Companies
  • Hospitals and Laboratories
  • Medical Research Laboratories
  • Academic Medical Institutes and Universities 
SegmentationsAsia Pacific sterility testing market is segmented on the basis of products, types of test, application, and end users.
On basis of type of product the market is segmented into instrument, reagent & services, kits and others.
On the basis of type of tests, the market is segmented into membrane filtration sterility testing, direct incubation sterility testing, direct transfer and others.
 On Application, the market is segmented into pharmaceutical & biological manufacturing, medical devices manufacturing, and others.
On the basis of end user, they are segmented into pharmaceuticals, hospital & laboratories and other.
Regional AnalysisOn the regional basis Asia Pacific is segmented into Japan, India, China, the republic of Korea, Australia and the Rest of Asia Pacific.
Japan holds a major shares of the market owing to increase in number of approval of new drugs and high spending on quality control.
China and India has a growing market due to huge population base, increasing demand for the better quality products, rapidly changing economy, increasing healthcare expenditure, and increasing number of pharmaceutical & biotechnological companies.
Reports suggest that China and Southeast Asia are poised to join the ranks of the high-growth Asian economies such as Korea and Taiwan
Rest of Asia Pacific holds the least share in the market.
Increasing number of healthcare organizations like hospital, private research institute has led to increase in the market in India.

Key Players
Some of the major player in the market are Avance Biosciences (U.S.), Boston Scientific Corporation (U.S.), Paragon Bioservices, Inc (U.S.), Merck KGaA (Germany), Thermo Fisher Scientific, Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), Avista Pharma Solutions (U.S.), and DYNALABS LLC. (U.S.)

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels: , , ,
Subscribe to: Posts (Atom)